Hofseth Biocare ASA: SUCCESSFULLY COMPLETED SEED ROUND CAPITAL RAISE IN HBC IMMUNOLOGY LLC AT $20M VALUATION FOR THE DEVELOPMENT OF A NEW PROSTATE CANCER CO-THERAPY
August 17, 2023 02:58 ET
|
Hofseth Biocare ASA
HBC Immunology LLC (“HBCI” or the “Company”), a majority owned subsidiary of Hofseth BioCare ASA (“HBC”), has successfully completed the required minimum seed capital financing of approx. USD 900,000...
Curium Announces Achievement of Co-Primary Endpoints in Phase 2 of Its Phase 1/2 SOLAR Clinical Trial Imaging Men With Histologically-Proven Prostate Cancer Using Copper Cu 64 PSMA I&T
August 15, 2023 10:50 ET
|
Curium
PARIS, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the positive results of the multi-center, open-label, Phase 2 SOLAR study of Copper Cu 64 PSMA...
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
August 15, 2023 07:05 ET
|
Myriad Genetics, Inc.
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.,...
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023 07:00 ET
|
Arvinas Inc.
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471), including VERITAC-2 2L Phase 3 trial and study lead-in for the VERITAC-3 1L Phase 3 trial, both in ER+/HER2-...
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
July 31, 2023 16:30 ET
|
Arvinas Inc.
NEW HAVEN, Conn. and NEW YORK, July 31, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that the U.K. Innovative Licensing and Access Pathway...
Curium Receives Marketing Authorization in the EU for PYLCLARI™, an Innovative 18F-PSMA PET Tracer Indicated in Adults With Prostate Cancer
July 28, 2023 06:12 ET
|
Curium
PARIS, July 28, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that the European Commission has granted marketing authorization for PYLCLARI™ (INN: Piflufolastat...
Global Radiation Oncology Market Expected to Reach $21.14 Billion by 2030: Technological Advancements and Global Cancer Burden Drive Growth
July 25, 2023 07:08 ET
|
Research and Markets
Dublin, July 25, 2023 (GLOBE NEWSWIRE) -- The "Radiation Oncology Market Size, Share & Trends Analysis Report By Type (External Beam Radiation Therapy, Internal Beam Radiation Therapy), By...
Curium Announces License and Development Agreement With Lantheus for AI-Based PSMA PET Software in Europe
July 25, 2023 06:06 ET
|
Curium
Builds on existing collaboration between Curium and Lantheus for prostate cancer PSMA-targeted PET imagingDeep-learning platform for standardization of comprehensive reporting in Europe PARIS, July ...
AI in Oncology Market Report 2023-2033: Accelerated Drug Discovery and Targeted Therapies Driving Growth
July 21, 2023 06:13 ET
|
Research and Markets
Dublin, July 21, 2023 (GLOBE NEWSWIRE) -- The "Artificial Intelligence (AI) in Oncology Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering. The global revenue for...
Oncology Biomarkers Global Market to 2028: Increased Availability and Ease of Biomarker Testing Fuels the Sector
July 04, 2023 05:13 ET
|
Research and Markets
Dublin, July 04, 2023 (GLOBE NEWSWIRE) -- The "Oncology Biomarkers: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global oncology biomarkers market reached a...